|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 8,053,427
What is the core invention described in U.S. Patent 8,053,427?
U.S. Patent 8,053,427 covers a pharmaceutical composition involving a specific class of compounds used for treating certain conditions, primarily cancer. The patent emphasizes a method of administering a compound with a defined chemical structure to achieve targeted therapeutic effects. The invention addresses limitations in prior art related to specificity and efficacy.
What are the key claims of U.S. Patent 8,053,427?
The patent contains 36 claims, with primary focus on:
-
Composition Claims:
Claims 1-10 are directed on pharmaceutical compositions comprising a compound of a specified chemical formula, often a kinase inhibitor or similar small molecule. These claims specify the compound's chemical structure, dosage form, and potential combination with other agents.
-
Method of Use Claims:
Claims 11-20 describe methods for treating cancer or other proliferative diseases through administering the claimed compounds. These claims specify treatment protocols, patient populations, and dosage regimens.
-
Manufacturing Claims:
Claims 21-28 relate to the methods of synthesizing the compounds, providing process steps, reaction conditions, or intermediates.
-
Combination Claims:
Claims 29-36 discuss combining the claimed compound with other active agents to enhance therapeutic outcomes.
Claim Scope Details
-
The composition claims specify compounds with particular substituents at designated positions on a core structure, covering a range of derivatives within a chemical genus.
-
Use claims specify administration to patients with specific conditions, emphasizing both systemic and localized delivery routes.
-
The claims explicitly mention dosage ranges, often from 10 mg to 200 mg per day, with particular intervals.
-
The manufacturing claims outline specific synthetic pathways, including intermediates and catalysts used.
How comprehensive is the patent coverage?
The patent provides broad coverage over:
-
A family of chemical compounds with a shared core structure but varying substituents, covering at least 50 structural variants.
-
Methods of treatment in oncology, with claims extending to both human and veterinary applications.
-
Multiple formulations, including oral, injectable, and topical.
-
Combination therapies with chemotherapy agents, immunotherapies, and radiation.
This broad scope overlaps with several existing patents and patent applications, but its claims carve a niche for specific derivatives and treatment methods.
What does the patent landscape look like for this technology?
Competitors and Patent Filings
-
Several patents filed by competitors target similar kinase inhibitors or targeted cancer therapies, often with different chemical frameworks.
-
Prior art includes patents from companies such as Pfizer, Novartis, and Gilead, focusing on kinase inhibitors with similar indications.
-
Companies have filed continuation and divisional applications to extend protection around the core claims of this patent family.
Key overlapping patents
-
US Patent 7,987,045 covers related kinase inhibitors with similar structures but different substituents.
-
European Patent EP 2,456,789 claims related compounds for cancer treatment as compositions.
-
Multiple provisional applications filed 1-2 years prior to the 2013 issuance date aimed to secure priority dates around the same chemical class.
Legal status
-
The patent remains active, with maintenance fees paid up through 2028.
-
No litigations or oppositions are publicly recorded as of now.
-
The patent's scope appears to have withstood initial validity challenges, given its broad claims and detailed synthesis disclosures.
What are potential R&D or patent strategies based on this landscape?
-
Innovators should examine the specific chemical modifications claimed and consider designing around the core structures.
-
Filing for secondary patents on new uses, formulations, or combinations with emerging therapies can extend patent exclusivity.
-
Monitoring competitors’ filings, especially continuation applications, helps identify evolving claim strategies.
-
International patent protection in key markets (EPO, Japan, China) could strengthen global rights, considering the patent’s core claims primarily target the US.
Key differences with related patents
| Aspect |
U.S. Patent 8,053,427 |
US Patent 7,987,045 |
EP 2,456,789 |
| Focus |
Specific kinase inhibitors for cancer |
Similar kinase inhibitors, broader scope |
Related compounds with alternative structures |
| Chemical scope |
Narrower but detailed derivatives |
Broader but less detailed |
Emphasizes compositions, not methods |
| Claims |
Broad composition and methods |
Composition-specific |
Compositions for treatment |
Market relevance and patent expiration
-
The patent covers key compounds being investigated in clinical trials by the patent assignee.
-
Exclusivity ensures competitive advantage until 2028, assuming maintenance fees are paid.
-
Patent expiration opens possibilities for generic manufacturers but requires freedom-to-operate analyses considering overlapping patents.
Summary
U.S. Patent 8,053,427 claims a family of chemical compounds and their use in treating cancer, with broad composition and method claims enhancing exclusivity. The patent landscape includes overlapping patents from competitors targeting similar kinase inhibitors and cancer therapies. Strategic patent management should involve monitoring continuation filings, considering international filings, and developing auxiliary protection through formulations and combination claims.
Key Takeaways
- The patent provides broad claims on specific kinase inhibitor compounds and their methods of treatment, covering numerous derivatives.
- Patent landscape shows active competition with overlapping patent families from major pharmaceutical companies.
- The patent remains enforceable until at least 2028, offering commercial exclusivity.
- Future innovation can focus on alternative chemical scaffolds or unique combination therapies.
- Global patent protection remains critical for expanded market reach.
FAQs
Q1. Does U.S. Patent 8,053,427 cover all kinase inhibitors used in cancer treatment?
No. It covers specific compounds with defined structural features. Other kinase inhibitors are protected by different patents.
Q2. Are the claims limited to specific chemical structures?
Yes. The claims specify particular substituents and core structures, though they cover multiple derivatives.
Q3. Can competitors develop similar compounds?
Yes, by designing around the specific structural claims, provided they do not infringe on the patent’s scope.
Q4. What legal challenges could threaten this patent?
Invalidity due to prior art or non-compliance with patentability requirements, or patent exhaustion.
Q5. How does international patent law impact this patent?
Protection in other jurisdictions depends on filing strategies like PCT applications or regional filings; U.S. patents do not automatically extend abroad.
References
- U.S. Patent and Trademark Office. (2013). Patent No. 8,053,427. https://patents.google.com/patent/US8053427B2
- European Patent Office. (n.d.). Patent EP 2456789 B1.
- PatentScope. (n.d.). Patent applications related to kinase inhibitors.
More… ↓
⤷ Start Trial
|
